Study of the Guardian System on Motor Recovery and Impact on Length of Stay in Ischemic Stroke Patients
Status: | Not yet recruiting |
---|---|
Conditions: | Peripheral Vascular Disease, Neurology |
Therapuetic Areas: | Cardiology / Vascular Diseases, Neurology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 9/19/2018 |
Start Date: | October 30, 2018 |
End Date: | March 28, 2019 |
Contact: | Fern Cudlip, MSN FNP CNRN NVRN ANVP FNCS |
Email: | Fern.cudlip@hcahealthcare.com |
Phone: | 408-724-0979 |
A Randomized, Non-Blinded Clinical Trial of a Non-Invasive Perfusion Enhancement System (Guardian System) on Motor Recovery and Impact on Length of Stay in Mobility Impaired Ischemic Stroke Patients
This is a non-blinded randomized study that will investigate whether the use of a novel,
non-invasive perfusion enhancement system (The Guardian System) impacts motor recovery and
hospital length of stay in acute ischemic stroke patients.
non-invasive perfusion enhancement system (The Guardian System) impacts motor recovery and
hospital length of stay in acute ischemic stroke patients.
This clinical research study is a prospective, non-blinded randomized clinical trial. The
study protocol and consent form have been approved by the IRB at the Study Institution. As
per the study design, consecutive adult patients admitted to the neuro-intensive care unit,
with acute ischemic stroke, meeting the inclusion and exclusion criteria will be consented
and enrolled in the study. Both the Study and Control groups will receive the standard of
care for ischemic stroke according to the hospitals' protocols, policies and procedures.
After obtaining informed consent, patients in the study arm will have the non-invasive
perfusion enhancement system (The Guardian System) placed on their beds and chairs. The
inflatable surfaces (the enhancers) will be placed directly on the mattress and chair under
the fitted sheet and bed linens. They will be secured with a non-porous, non-slip silicone
attacher. An adaptive pressure controller will be attached to the perfusion enhancer through
a connector set. The adaptive pressure controller will be secured to the bed foot board or
side rail and have the ability to be secured to an Intravenous pole as necessary. Specific
data points for each patient in the Experimental group will be entered into the Controller:
they include the patient's weight in kilograms and the patient's position (bed or chair).
This study seeks to evaluate the device's effect on motor recovery and length of stay in a
homogeneous ischemic stroke population that will be randomized for use of the novel
non-invasive perfusion enhancement device from admission to discharge.
study protocol and consent form have been approved by the IRB at the Study Institution. As
per the study design, consecutive adult patients admitted to the neuro-intensive care unit,
with acute ischemic stroke, meeting the inclusion and exclusion criteria will be consented
and enrolled in the study. Both the Study and Control groups will receive the standard of
care for ischemic stroke according to the hospitals' protocols, policies and procedures.
After obtaining informed consent, patients in the study arm will have the non-invasive
perfusion enhancement system (The Guardian System) placed on their beds and chairs. The
inflatable surfaces (the enhancers) will be placed directly on the mattress and chair under
the fitted sheet and bed linens. They will be secured with a non-porous, non-slip silicone
attacher. An adaptive pressure controller will be attached to the perfusion enhancer through
a connector set. The adaptive pressure controller will be secured to the bed foot board or
side rail and have the ability to be secured to an Intravenous pole as necessary. Specific
data points for each patient in the Experimental group will be entered into the Controller:
they include the patient's weight in kilograms and the patient's position (bed or chair).
This study seeks to evaluate the device's effect on motor recovery and length of stay in a
homogeneous ischemic stroke population that will be randomized for use of the novel
non-invasive perfusion enhancement device from admission to discharge.
Inclusion Criteria:
- Only Acute Ischemic Stroke Patients
- Baseline Modified Rankin Score of less than or equal to 0-2
- Remains hemiplegic (left or right) with motor component score on National Institute of
Stroke Health Scale of 2-4 on arm/leg with or without thrombectomy/tissue plasminogen
activator
- Insured (Medicare or private)
Exclusion Criteria:
- Dementia or Alzheimer Diagnosis
- Concurrent hemodialysis
- Obesity with Body Mass Index greater than 33
- Baseline Modified Rankin Score of 3 to 5
- Patients requiring ventilator support of greater than 2 days
- Peripheral neuropathy
- Concurrent deep vein thrombosis or venous thromboembolism
- Presence of concurrent pre-existing pressure injury
- Prolonged inconsistent use of perfusion therapy defined as two or more consecutive
hours off of the perfusion enhancement device
We found this trial at
1
site
Click here to add this to my saved trials